Prognosis in autoimmune and infectious disease: new insights from genetics

Clinical and Translational Immunology

Volumn 3, Issue 5, 2014, Pages

  Lee, James C ^a,b   Smith, Kenneth G C ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

autoimmunity; FOXO3; genetics; infection; prognosis

Indexed keywords

EID: 84961708068     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2014.8     Document Type: Review

References (37)

1. Fisher RA. The correlation between relatives on the supposition of Mendelian inheritance. Philos Trans R Soc Edin 1918; 52: 399–433.
2. Wellcome Trust Case Control Consortium. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661–678.
3. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119–124.
4. McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010; 141: 210–217.
5. Crow TJ. ‘The missing genes: what happened to the heritability of psychiatric disorders’. Mol Psychiatry 2011; 16: 362–364.
6. Lee JC, Espeli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013; 155: 57–69.
7. McKinney EF, Lyons PA, Carr EJ, Hollis JL, Jayne DR, Willcocks LC et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010; 16: 586–591 581p following 591.
8. Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121: 4170–4179.
9. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421–426.
10. Ouyang W, Beckett O, Ma Q, Paik JH, DePinho RA, Li MO. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol 2010; 11: 618–627.
11. Harada Y, Elly C, Ying G, Paik JH, DePinho RA, Liu YC. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J Exp Med 2010; 207: 1381–1391.
12. Kerdiles YM, Stone EL, Beisner DR, McGargill MA, Ch'en IL, Stockmann C et al. Foxo transcription factors control regulatory T cell development and function. Immunity 2010; 33: 890–904.
13. Dejean AS, Beisner DR, Ch'en IL, Kerdiles YM, Babour A, Arden KC et al. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 2009; 10: 504–513.
14. Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011; 121: 1361–1372.
15. Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009; 41: 1011–1015.
16. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7–19.
17. Hugosson E, Montgomery SM, Premji Z, Troye-Blomberg M, Bjorkman A. Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol 2004; 26: 111–117.
18. Weersma RK, Stokkers PC, van Bodegraven AA, van Hogezand RA, Verspaget HW. de Jong DJ, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009; 58: 388–395.
19. Cleynen I, Mahachie John JM, Henckaerts L, Van Moerkercke W, Rutgeerts P, Van Steen K et al. Molecular reclassification of Crohn's disease by cluster analysis of genetic variants. PLoS One 2010; 5: e12952.
20. Annese V, Lombardi G, Perri F, D'Inca R, Ardizzone S, Riegler G et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease—an IG-IBD study. Am J Gastroenterol 2005; 100: 84–92.
21. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123: 679–688.
22. Hindorff LA, MacArthur J, Morales J, Junkins HA, Hall PN, Klemm AK et alA Catalog of Published Genome-Wide Association Studies. Available at: http://www.genome.gov/gwastudies 2013 Accessed December 2013.
23. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012; 90: 636–647.
24. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359: 2767–2777.
25. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992–3995.
26. Sambo F, Trifoglio E, Di Camillo B, Toffolo GM, Cobelli C. Bag of Naive Bayes: biomarker selection and classification from genome-wide SNP data. BMC Bioinformatics 2012; 13 (Suppl 14): S2.
27. de Los Campos G, Vazquez AI, Fernando R, Klimentidis YC, Sorensen D. Prediction of complex human traits using the genomic best linear unbiased predictor. PLoS Genet 2013; 9: e1003608.
28. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612–1619.
29. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008; 358: 1240–1249.
30. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg J, Pedersen BK, Jeune B. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med 2003; 115: 278–283.
31. Horrillo D, Sierra J, Arribas C, Garcia-San Frutos M, Carrascosa JM, Lauzurica N et al. Age-associated development of inflammation in Wistar rats: Effects of caloric restriction. Arch Physiol Biochem 2011; 117: 140–150.
32. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92–105.
33. Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005; 2: 8.
34. Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, Nikolaus S et al. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci USA 2009; 106: 2700–2705.
35. Anselmi CV, Malovini A, Roncarati R, Novelli V, Villa F, Condorelli G et al. Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Res 2009; 12: 95–104.
36. Soerensen M, Dato S, Christensen K, McGue M, Stevnsner T, Bohr VA et al. Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data. Aging Cell 2010; 9: 1010–1017.
37. Ziv E, Hu D. Genetic variation in insulin/IGF-1 signaling pathways and longevity. Ageing Res Rev 2011; 10: 201–204.